WARMINSTER, Pa., Oct. 03, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced its decision to discontinue the clinical development of AB-506, an oral… Read More
SEPTEMBER 27, 2019, AbCellera, a biotech focusing on the discovery of therapeutic antibodies, is one of Vancouver’s top 10 fastest growing companies, according to the Globe and Mail’s list of… Read More
SAN DIEGO, and VANCOUVER, British Columbia, Sept. 23, 2019 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a clinical stage biotechnology company developing precise cancer therapeutics targeting essential kinases, received clearance from the Food and Drug Administration (FDA)… Read More
WARMINSTER, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be participating in the following investor… Read More
Vancouver, Sep 24, 2019 – PR Associates is a science-based communications and training consultancy with specialized experience in developing and delivering integrated training and strategies that support reputation management and… Read More
